Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)

Many people living with HIV struggle to consistently adhere to antiretroviral therapy, fail to achieve long-term virologic control and remain at risk for HIV-related disease progression, development of resistance and may transmit HIV infection to others. To determine if switching from current multi-...

Full description

Saved in:

Bibliographic Details
Published in:	Patient preference and adherence Vol. 16; pp. 3267 - 3281
Main Authors:	Klein, Marina B, Young, Jim, Ortiz-Paredes, David, Wang, Shouao, Walmsley, Sharon, Wong, Alexander, Martel-Laferrière, Valérie, Pick, Neora, Conway, Brian, Angel, Jonathan, Baril, Jean-Guy, Fraser, Chris, Lebouché, Bertrand, Tan, Darrell H S, Sandre, Roger, Trottier, Sylvie, Peiris, Hansi, Jayaraman, Jayamarx, Singer, Joel
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01-01-2022 Taylor & Francis Ltd Dove
Subjects:	Abacavir Antiretroviral drugs Drug resistance Drug therapy Drug therapy, Combination Evaluation Hepatitis HIV HIV infection Human immunodeficiency virus Infections Intervention Lamivudine Mutation Original Research Patient compliance Patients Testing Canada human immunodeficiency virus adherence interventions HIV vulnerable populations single tablet regimen antiretroviral therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Many people living with HIV struggle to consistently adhere to antiretroviral therapy, fail to achieve long-term virologic control and remain at risk for HIV-related disease progression, development of resistance and may transmit HIV infection to others. To determine if switching from current multi-tablet (curART) to single-tablet antiretroviral therapy (abacavir/lamivudine/dolutegravir; ABC/3TC/DTG), both combined with individualized adherence support, would improve HIV suppression in non-adherent vulnerable populations. TriiADD was an investigator-initiated randomized, multicentre, open label study. HIV+ adults with documented non-adherence on curART were randomized in a 1:1 ratio to immediately switch to ABC/3TC/DTG or to continue curART. Both arms received adherence support. The primary outcome was the proportion of participants in each arm with HIV RNA < 50 copies/mL 24 weeks after randomization. In total, 50 people were screened and 27 randomized from 11 sites across Canada before the trial was stopped early due to slow recruitment. Participants were predominantly from ethnocultural communities, Indigenous people and/or had a history of injection drug use. The proportion achieving HIV RNA < 50 copies/mL at week 24 was 4/12 (33%) in the curART arm vs 7/13 (54%) in the ABC/3TC/DTG arm; median Bayesian risk difference, 5% (95% CrI, -17 to 28%) higher for those randomized to ABC/3TC/DTG. We encountered difficulties with recruitment of participants without prior drug resistance, retention despite intensive support, reliably measuring adherence and in overcoming entrenched adherence barriers. Results of our trial are consistent with a slight improvement in viral suppression in a vulnerable population when a single tablet regimen is combined with patient-level adherence support. Beyond treatment simplicity and tolerability, tailored interventions addressing stigma and social determinants of health are still needed. The numerous challenges we encountered illustrate how randomised trials may not be the best approach for assessing adherence interventions in vulnerable populations.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1177-889X 1177-889X
DOI:	10.2147/PPA.S379065